

# L A I S

## LONG ACTING ANTIRETROVIRAL INJECTABLES

### HOW ARE LONG-ACTING ANTIRETROVIRAL INJECTIONS PRESCRIBED FOR HIV PREVENTION IN ADOLESCENTS AND ADULTS?

Cabotegravir extended-release injectable suspension (APRETUDE) is administered first as two initiation injections (600 mg, 3 mL) administered one month apart, and then every two months thereafter. Cabotegravir oral tablets may be administered for one month before initiating the first injection to assess tolerability to the medication.

Cabotegravir extended-release injectable suspension for HIV prevention was approved by the FDA in December of 2021 for use in adults and adolescents<sup>1</sup>.

**Individuals must have a negative HIV-1 test prior to initiating the cabotegravir injectable prevention regimen.**

<sup>1</sup> Weighing at least 35 kg or 77 pounds.

The efficacy of cabotegravir extended-release injectable suspension as PrEP was evaluated in two studies conducted by the HIV Prevention Trials Network (HPTN). One study, HPTN 083, enrolled cisgender men and transgender women who have sex with cisgender men, and the HPTN 084 study enrolled cisgender women. The efficacy of cabotegravir extended-release injectable suspension as PrEP was found to be extremely effective at preventing the acquisition of HIV.

Talk to your health care provider to find out if cabotegravir extended-release injectable suspension (APRETUDE) is the right HIV prevention method for you.